Upstream Bio

Upstream Bio: Revolutionizing Healthcare with Innovative Therapies

Upstream Bio, with the slogan "We strive to reach the source of inflammation and conquer it," is a pioneering biotech startup founded in 2021. The company's primary focus is on developing groundbreaking therapies targeting inflammation and allergic diseases. Their lead program entails a clinical-stage monoclonal antibody that inhibits the TSLP receptor, a validated target upstream of multiple signaling cascades affecting various immune cells crucial to both common and rare diseases.

Leveraging their diverse roots and substantial industry experience, Upstream Bio aims to make a significant impact on patients and their families by alleviating the burden of inflammatory and allergic conditions. Their commitment to innovation and patient-centric solutions has garnered widespread attention and support from investors.

The company recently secured a noteworthy $200.00M Series B investment on 08 June 2023. Notable investors in this round included HBM Healthcare Investments, Wellington Management, Access Biotechnology, Decheng Capital, Enavate Sciences, HBM Partners, Samsara BioCapital, Venrock Healthcare Capital Partners, Altshuler Shaham, and Bain Capital Life Sciences. This substantial investment is a testament to the confidence and belief these prominent investors have in Upstream Bio's potential to drive significant change within the biotechnology, healthcare, and pharmaceutical industries.

Upstream Bio's headquarters are located in the United States, positioning them at the forefront of innovation in the global healthcare and biotech sectors. With this recent injection of capital and strong investor backing, Upstream Bio is poised to continue making strides in developing transformative therapies for patients grappling with inflammatory and allergic diseases, solidifying its position as a leading player in the biotech landscape.